Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Novartis' Cosentyx Boosted By High Psoriasis Skin Clearance Over 4 Years

Executive Summary

Data showing Novartis' Cosentyx maintained high levels of skin clearance in psoriasis patients along with a favorable safety profile after four years should give the drug an advantage over new interleukin inhibitors undergoing Phase III trials in psoriasis.

Advertisement

Related Content

Clever Marketing Needed To Position J&J's New Psoriasis Drug Ahead Of Cheaper Options
New Data Bolsters Cosentyx In AS & PsA; Humira Head-To-Head Planned

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register